Ignite Creation Date:
2025-12-24 @ 1:06 PM
Ignite Modification Date:
2025-12-30 @ 8:04 PM
Study NCT ID:
NCT05586061
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-02-07
First Post:
2022-10-16
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
First-line Treatment with RC48 Plus Tislelizumab and S-1(RCTS) in Advanced Gastric Cancer
Sponsor:
Qilu Hospital of Shandong University
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-02-10
Start Date Type:
ACTUAL
Primary Completion Date:
2024-12-29
Primary Completion Date Type:
ACTUAL
Completion Date:
2025-12-31
Completion Date Type:
ESTIMATED
First Submit Date:
2022-10-16
First Submit QC Date:
None
Study First Post Date:
2022-10-19
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-02-05
Last Update Post Date:
2025-02-07
Last Update Post Date Type:
ACTUAL